Market Research Report
Hospital Acquired Infections Therapeutic Market Size, Share & Trends Analysis Report By Drug Class (Antibacterial Drugs, Antiviral Drugs, Antifungal Drugs), By Infection Type, By Region, And Segment Forecasts, 2020 - 2027
|Published by||Grand View Research, Inc.||Product code||989735|
|Published||Content info||120 Pages
Delivery time: 2-3 business days
|Hospital Acquired Infections Therapeutic Market Size, Share & Trends Analysis Report By Drug Class (Antibacterial Drugs, Antiviral Drugs, Antifungal Drugs), By Infection Type, By Region, And Segment Forecasts, 2020 - 2027|
|Published: February 11, 2021||Content info: 120 Pages||
The global hospital acquired infections therapeutic market size is expected to reach USD 12.5 billion by 2027, according to a new report by Grand View Research, Inc. The market is expected to expand at a CAGR of 2.4% from 2020 to 2027. The high prevalence of HAIs, rise in approval and launch of new drugs, and growing hospitalization due to the rise in prevalence of chronic diseases are driving the market.
According to the data published by the New York State Department of Health in November 2019, around 160 hospitals in New York reported total cases of around 1,139 colon SSIs out of 19,732 procedures in 2018, a rate of 5.8 infections per 100 procedures. The same source also states that in 2018, around 15,310 cases of Clostridioides difficile infections (CDI) were reported in acute care hospitals located in New York. Such, high prevalence of hospital-acquired infections is anticipated to significantly raise the demand for its treatment therapies and support the HAIs therapeutics market growth over the forecast period.
Furthermore, key players in the market are involved in extensive R&D initiatives for the development and indication expansion of its already approved drugs for HAI treatment. For instance, in February 2018, the FDA approved Allergan plc's supplemental New Drug Application (sNDA) and expanded the approval of Avycaz (ceftazidime and avibactam) to include the treatment of HABP/VABP and hospital-acquired bacterial pneumonia.